Tessera Therapeutics is a biotechnology company developing Gene Writing™, a novel approach that enables the writing of therapeutic messages directly into the genome. This technology aims to address diseases at their source, potentially creating a transformative category within genetic medicine that overcomes the limitations of existing gene therapy and editing methods. Founded by Flagship Pioneering, Tessera is committed to advancing human health and sustainability through its pioneering research and development initiatives. Their mission encompasses delivering innovative solutions for previously untreatable conditions, with a strong emphasis on collaboration, integrity, and continuous growth within the organization. This environment fosters the professional development of its team members while striving to make significant contributions to the field of genetic medicine.